PUNE, India, June 6, 2016 /PRNewswire/ --
According to a new market research report " Viral Inactivation Market By Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs)- Global Forecast to 2021", published by MarketsandMarkets, The global market was valued at USD 320.5 Million in 2016. This market is expected to grow at a CAGR of 12.3% to reach USD 573.0 Million in 2021.
Browse 72 market data Tables with 70 Figures spread through 154 Pages and in-depth TOC on "Viral Inactivation Market"
Early buyers will receive 10% customization on this report.
The report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global viral inactivation market along with the estimates and forecasts of the revenue and market share analysis.
The global viral inactivation market is segmented on the basis of method, product, application, end user, and geography. By method, the market is divided into solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light. Of these, the solvent detergent method segment accounted for the largest share of the global viral inactivation market in 2015.
The application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Of these the vaccines and therapeutics application hold the highest share.
By end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
Rapidly increasing pharmaceutical and biotechnology industries and increasing number of new biologics products launched will be the two most important growth drivers for this market in the forecasted period (2016-2021). For instance, the number of new biologics products launched annually witnessed a strong upward trend between 2003 and 2013. The number of new products launched in 2013 was 56 as compared to 29 in 2003. The biologics pipeline has increased by 155%, from 355 treatments in 2001 to 907 in 2012. A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industry, which is an important end user of viral inactivation products.
The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S. Asia segment is further divided into China, Japan, India, and Rest of Asia.
Talk to our Experts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=121427017
Major players in the Viral Inactivation Market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).
Browse Related Reports:
Virus Filtration Market by Product (Kits & Reagents, Systems, Services), Application (Biologics (Vaccine & Therapeutics, Blood, Tissues, Stem Cells), Devices, Air, Water Purification), End User (Biopharmaceutical, CROs, Research) - Global Forecast to 2020
Mycoplasma Testing Market by Products (Instruments, Kits & Reagents, Services), Application (Cell Line, Virus, End of Production Cells), Technology (PCR, ELISA, Direct Assay), End User (Cell Banks, Pharmaceutical Companies) - Global Forecast to 2019
MarketsandMarkets is the world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets